UK-based drugmaker EUSA Pharma and China’s BeiGene (HKEX: 06160) have entered into an exclusive development and commercialization agreement for the orphan biologic products Sylvant (siltuximab) and Qarziba (dinutuximab beta).
Sylvant is currently approved in more than 40 countries for the treatment of idiopathic multicentric Castleman’s disease (iMCD), a rare, life-threatening and debilitating condition.
Qarziba is the only targeted immunotherapy approved by the European Medicines Agency for the treatment of high-risk neuroblastoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze